STOCK TITAN

Athira Pharma (ATHA) Financials

ATHA NASDAQ

Ticker history: ATHA became LONA (LeonaBio, Inc.) on .

Trailing 12 months to March 31, 2026
Revenue Not reported for the trailing 12 months
Net Income -$129.4M n/m YoY
EPS (Diluted) -$24.70 FY2025 annual
Operating Cash Flow -$52.0M n/m YoY
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATHA SEC filings page.

This page shows Athira Pharma, Inc. (ATHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATHA FY2025

Athira’s reported model remains loss-funded, while FY2025 financing and liabilities reshaped a once-equity-heavy balance sheet.

FY2025 operating cash outflow was $45.7M against a net loss of $106.0M, so cash use was materially below the accounting loss. That earnings-to-cash gap means reported profitability alone does not explain the company’s funding pattern.

No revenue is reported through FY2025, so the statements do not show a sales-funded operating engine or evidence of commercial scale. Research spending fell 75.2% to $17.5M, yet the company still recorded a substantial operating loss, indicating the disclosed structure remains research-led rather than revenue-led.

Financing cash flow of $82.5M outweighed the operating cash outflow of $45.7M in FY2025, indicating cash movement leaned on financing rather than operations. Compared with FY2024, liabilities-to-equity was 2.3x and current ratio was 1.9x in FY2025; leverage increased as short-term coverage narrowed.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Athira Pharma, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
2/6

Athira Pharma, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Athira Pharma, Inc. reported a net loss of $106.0M while operations used $45.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$17.0M
YoYn/m

Athira Pharma, Inc.'s EBITDA was -$17.0M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net Income
-$32.9M
YoYn/m
QoQn/m

Athira Pharma, Inc. reported a net loss of $32.9M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.73

Athira Pharma, Inc. earned -$1.73 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt
$32.8M
YoY+24.3%
QoQ-52.6%
5Y CAGR-23.8%

Athira Pharma, Inc. held $32.8M in cash as of Q1 2026; no long-term debt figure is on record for that period.

Shares Outstanding
9M
QoQ+0.6%

Athira Pharma, Inc. had 9M shares outstanding in Q1 2026. Against the prior quarter it is up 0.6%.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity
-66.8%
YoY-42.3pp
QoQ+231.4pp

Athira Pharma, Inc.'s quarterly ROE was -66.8% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is down 42.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 231.4 percentage points.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending
$11.3M
YoY+161.8%
QoQ+67.8%

Athira Pharma, Inc. invested $11.3M in research and development in Q1 2026. This represents an increase of 161.8% from the same quarter a year earlier. Against the prior quarter it is up 67.8%.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

ATHA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATHA quarterly income statement
MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
R&D Expenses$11.3M+161.8%$6.7M-28.4%$2.8M-84.2%$3.7M-83.5%$4.3M-79.7%$9.4M$17.9M-34.1%$22.2M+2.5%
SG&A Expenses$6.9M+31.5%$3.8M-39.2%$4.0M-46.5%$3.6M-38.2%$5.2M-18.9%$6.2M$7.6M-3.4%$5.9M-41.4%
Operating Income-$17.2Mn/m-$78.6Mn/m-$6.9Mn/m-$7.3Mn/m-$9.5Mn/m-$15.6M-$29.6Mn/m-$28.0Mn/m
EBITDA-$17.0Mn/mN/A-$6.7Mn/m-$7.1Mn/m-$9.3Mn/mN/A-$29.4Mn/m-$27.8Mn/m
Net Income-$32.9Mn/m-$82.9Mn/m-$6.6Mn/m-$7.0Mn/m-$9.1Mn/m-$15.0M-$28.7Mn/m-$26.9Mn/m
EPS (Basic)-$1.73N/A-$1.68-$0.18-$2.34N/A-$7.46-$7.00
EPS (Diluted)-$1.73N/A-$1.68-$0.18-$2.34N/A-$7.46-$7.00
Diluted Shares (Avg)19MN/A4M39M4MN/A4M38M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

ATHA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATHA quarterly balance sheet
MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Total Assets$71.6M+64.5%$92.2M+56.8%$30.0M-65.2%$35.5M-68.1%$43.5M-67.4%$58.8M-63.3%$86.2M-53.3%$111.3M-46.5%
Current Assets$69.2M+73.6%$89.5M+63.1%$27.0M-67.0%$32.2M-69.8%$39.9M-69.0%$54.8M-64.6%$82.0M-54.1%$106.7M-44.5%
Cash & Equivalents$32.8M+24.3%$69.3M+43.0%$20.9M-69.7%$19.9M-73.1%$26.4M-66.0%$48.4M-46.5%$68.9M-37.6%$73.8M-35.0%
Total Liabilities$22.3M+260.5%$64.4M+361.8%$3.2M-88.7%$3.6M-87.3%$6.2M-76.9%$13.9M-53.6%$28.7M-4.3%$27.9M+21.0%
Current Liabilities$6.7M+21.4%$47.5M+261.7%$2.8M-90.0%$3.0M-88.9%$5.5M-78.5%$13.1M-54.5%$27.8M-3.0%$26.9M+24.2%
Non-Current Liabilities$15.6M+2160.6%$16.9M+1999.4%$460K-49.6%$578K-43.1%$691K-38.2%$803K-34.0%$912K-30.6%$1.0M-27.8%
Total Equity$49.3M+32.1%$27.8M-38.0%$26.8M-53.5%$32.0M-61.6%$37.3M-65.0%$44.8M-65.6%$57.6M-62.8%$83.3M-54.9%
Retained Earnings-$544.7Mn/m-$511.8Mn/m-$428.9Mn/m-$422.3Mn/m-$415.3Mn/m-$406.1Mn/m-$391.1Mn/m-$362.4Mn/m

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

ATHA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATHA quarterly cash flow statement
MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Operating Cash Flow-$20.9Mn/m-$19.4Mn/m-$4.7Mn/m-$7.0Mn/m-$14.7Mn/m-$26.0Mn/m-$23.0Mn/m-$22.3Mn/m
Depreciation & Amortization$231K-4.9%N/A$200K0.0%$200K0.0%$243K+0.4%N/A$200K-18.0%$200K-18.0%
Stock-Based Compensation$662K-59.6%N/A$1.4M-52.0%$1.6M-50.2%$1.6M-38.9%N/A$2.9M+17.7%$3.2M+2.8%
Capital ExpendituresN/AN/AN/AN/AN/A$0n/m$0-100.0%$28K-15.2%
Free Cash FlowN/AN/AN/AN/AN/A-$26.0Mn/m-$23.0Mn/m-$22.4Mn/m
Investing Cash Flow-$15.5Mn/m-$14.6Mn/m$5.7M-68.7%$441K-98.3%-$7.4M-156.4%-$2.8M-144.0%$18.0M-12.8%$26.6M-18.2%
Financing Cash FlowN/A$82.4M+242361.8%$0-100.0%N/AN/A$34K-77.6%$12Kn/mN/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATHA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATHA quarterly financial ratios
MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Return on Equity-66.8%-42.3pp-298.3%-264.8pp-24.7%+25.2pp-21.8%+10.4pp-24.5%+0.2pp-33.5%-49.9%-28.6pp-32.2%-16.2pp
Return on Assets-46.0%-25.0pp-90.0%-64.4pp-22.0%+11.3pp-19.6%+4.5pp-21.0%-1.3pp-25.5%-33.3%-15.5pp-24.1%-9.9pp
Current Ratio10.38+3.1x1.88-2.3x9.70+6.7x10.81+6.8x7.26+2.2x4.18-1.2x2.95-3.3x3.97-4.9x
Liabilities-to-Equity0.45+0.3x2.32+2.0x0.12-0.4x0.11-0.2x0.17-0.1x0.31+0.1x0.50+0.3x0.34+0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Athira Pharma, Inc. ATHA FY2025 N/A -$106.0M N/A N/A —
Jade Biosciences, Inc. JBIO FY2025 N/A -$127.4M N/A $1.1B —
ArriVent BioPharma, Inc. AVBP FY2025 N/A -$166.3M N/A $552.9M —
C4 Therapeutics, Inc. CCCC FY2025 $35.9M -$105.0M N/A $332.2M 66/100
Kazia Therapeutics Limited KZIA FY2025 $28K -$13.6M N/A $82.6M —
Summit Therapeutics Inc. SMMT FY2025 N/A -$1.1B N/A $8.5B —

Frequently Asked Questions

No, Athira Pharma, Inc. (ATHA) reported a net loss of $129.4M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net loss of $106.0M.

Athira Pharma, Inc. (ATHA) reported diluted earnings per share of -$24.70 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Athira Pharma, Inc. (ATHA) had EBITDA of -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Athira Pharma, Inc. (ATHA) has a return on equity of -381.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Athira Pharma, Inc. (ATHA) recorded an outflow of $45.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Athira Pharma, Inc. (ATHA) had $92.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Athira Pharma, Inc. (ATHA) invested $17.5M in research and development during fiscal year 2025.

Athira Pharma, Inc. (ATHA) had 9M shares outstanding as of fiscal year 2025.

Athira Pharma, Inc. (ATHA) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.

Athira Pharma, Inc. (ATHA) had a liabilities-to-equity ratio of 2.32 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Athira Pharma, Inc. (ATHA) had a return on assets of -115.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Athira Pharma, Inc. (ATHA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Athira Pharma, Inc. (ATHA) reported a net loss of $106.0M while operations used $45.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top